《Managed Healthcare Executive》（MHE）近日专访了Renuka Iyer博士。Iyer于12月初被任命为美国国家综合癌症网络（NCCN）首席医学官（CMO），其目标是进一步强化循证肿瘤医疗，并拓展针对罕见癌种及多元人群的指南覆盖。在接受MHE采访时，Iyer就NCCN如何在治疗手段快速演进的背景下，持续提供高价值、循证导向的肿瘤医疗，分享了她的思考。

The National Comprehensive Cancer Network (NCCN) is collaborating with the Vietnam National Cancer Hospital (K Hospital) to ...

The NCCN’s updated guidelines for the treatment of breast cancer include updates on sentinel lymph node biopsy, ovarian function suppression, and the use of prognostic tools.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that ...

New NCCN guidelines recognize the utility of MammaPrint for guiding anthracycline therapy selection in HR+/HER2- early-stage ...

The National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology to include ...

The NCCN guidelines now include MammaPrint for identifying HR+/HER2- early-stage breast cancer patients who may benefit from ...

PharmaEssentia Announces Updated NCCN Clinical Practice Guidelines Include ropeginterferon alfa-2b-njft (BESREMi®) for ...

PLYMOUTH MEETING, PA [October 6, 2025] — Today, the National Comprehensive Cancer Network ® (NCCN ®)—a nonprofit responsible for globally utilized guidelines for cancer care—is sharing new NCCN ...

The NCCN has updated its guidelines on breast, pancreatic, colon, rectal, non-small cell lung, and other cancers. The National Comprehensive Cancer Network (NCCN) has updated its treatment guidelines ...

SALT LAKE CITY, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc (MYGN). (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that its Prolaris prostate cancer ...

PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles ...